These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37067982)

  • 1. Long-Acting Injectable Antipsychotics and Infections in Schizophrenia.
    Malham KM; Miller BJ
    J Clin Psychopharmacol; 2023 May-Jun 01; 43(3):259-262. PubMed ID: 37067982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies.
    Kishimoto T; Hagi K; Kurokawa S; Kane JM; Correll CU
    Lancet Psychiatry; 2021 May; 8(5):387-404. PubMed ID: 33862018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia.
    Huang CY; Fang SC; Shao YJ
    JAMA Netw Open; 2021 May; 4(5):e218810. PubMed ID: 33974056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
    Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
    Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort.
    Guinart D; Taipale H; Rubio JM; Tanskanen A; Correll CU; Tiihonen J; Kane JM
    Schizophr Bull; 2021 Oct; 47(6):1621-1630. PubMed ID: 34013325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia.
    Lafeuille MH; Dean J; Carter V; Duh MS; Fastenau J; Dirani R; Lefebvre P
    Curr Med Res Opin; 2014 Aug; 30(8):1643-55. PubMed ID: 24730586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
    Kishimoto T; Nitta M; Borenstein M; Kane JM; Correll CU
    J Clin Psychiatry; 2013 Oct; 74(10):957-65. PubMed ID: 24229745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia.
    Fang SC; Huang CY; Shao YJ
    J Clin Psychiatry; 2022 Jun; 83(4):. PubMed ID: 35649156
    [No Abstract]   [Full Text] [Related]  

  • 10. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics.
    Misawa F; Kishimoto T; Hagi K; Kane JM; Correll CU
    Schizophr Res; 2016 Oct; 176(2-3):220-230. PubMed ID: 27499361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.
    Lin D; Thompson-Leduc P; Ghelerter I; Nguyen H; Lafeuille MH; Benson C; Mavros P; Lefebvre P
    CNS Drugs; 2021 May; 35(5):469-481. PubMed ID: 33909272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality Risk Associated With Long-acting Injectable Antipsychotics: A Systematic Review and Meta-analyses of Randomized Controlled Trials.
    Kishi T; Matsunaga S; Iwata N
    Schizophr Bull; 2016 Nov; 42(6):1438-1445. PubMed ID: 27086079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics on Time to Rehospitalization Within 1 Year of Discharge in Elderly Patients With Schizophrenia.
    Lin CH; Chen FC; Chan HY; Hsu CC
    Am J Geriatr Psychiatry; 2020 Jan; 28(1):23-30. PubMed ID: 31481273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.
    Correll CU; Citrome L; Haddad PM; Lauriello J; Olfson M; Calloway SM; Kane JM
    J Clin Psychiatry; 2016; 77(suppl 3):1-24. PubMed ID: 27732772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.
    Kishimoto T; Robenzadeh A; Leucht C; Leucht S; Watanabe K; Mimura M; Borenstein M; Kane JM; Correll CU
    Schizophr Bull; 2014 Jan; 40(1):192-213. PubMed ID: 23256986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia.
    Potkin S; Bera R; Zubek D; Lau G
    BMC Psychiatry; 2013 Oct; 13():261. PubMed ID: 24131801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome.
    Olagunju AT; Clark SR; Baune BT
    Aust N Z J Psychiatry; 2019 Jun; 53(6):509-527. PubMed ID: 30957510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial disparities in utilization of first-generation versus second-generation long-acting injectable antipsychotics in Medicaid beneficiaries with schizophrenia.
    Pesa J; Liu Z; Fu AZ; Campbell AK; Grucza R
    Schizophr Res; 2023 Nov; 261():170-177. PubMed ID: 37778124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016-March 2019.
    Peters L; Krogmann A; von Hardenberg L; Bödeker K; Nöhles VB; Correll CU
    Curr Psychiatry Rep; 2019 Nov; 21(12):124. PubMed ID: 31745659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.